false
0001722964
0001722964
2024-02-29
2024-02-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): February 29, 2024
Y-MABS THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
| Delaware |
|
001-38650 |
|
47-4619612 |
|
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
230 Park Avenue
Suite 3350
New York, New York 10169
(Address of principal executive offices)
(Zip Code)
(646) 885-8505
(Registrant’s telephone number,
include area code)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class: |
|
Trading
Symbol |
|
Name of each exchange on which
registered: |
| Common Stock, $0.0001 par value |
|
YMAB |
|
NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial
Condition.
On February 29, 2024, Y-mAbs Therapeutics, Inc.,
announced its financial results for the quarter and full year ended December 31, 2023. A copy of the press release is attached hereto
as Exhibit 99.1.
The information furnished pursuant to Item 2.02 on this Form 8-K,
including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Y-MABS THERAPEUTICS, INC. |
| |
|
|
| Date: February 29, 2024 |
By: |
/s/ Michael Rossi |
| |
|
Michael Rossi |
| |
|
President and Chief Executive Officer |
Exhibit
99.1
Y-mAbs
Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
| · | Record
DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023
represents YoY growth of 42% and 71%, respectively |
| · | Cash
and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated
cash runway into 2027 |
| · | Management
announces full year 2024 financial guidance |
| · | The
Company will host a conference call on Friday, March 1, 2024, at 8:00 a.m. ET |
New York, NY,
February 29, 2024 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)
(Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for
the quarter and full year ended December 31, 2023.
“Y-mAbs has made significant progress
across both the development and commercial fronts of our business resulting in a momentous 2023,” said Mike Rossi, President and
Chief Executive Officer. “From a development standpoint, we demonstrated proof-of-concept of our Self-Assembly DisAssembly (“SADA”)
Pretargeted Radioimmunotherapy (“PRIT”) platform, showing that GD2-SADA targets and binds to tumors in humans in a Phase
1 trial. We continue to expect to present mature data from Part A of our Phase 1 GD2-SADA clinical trial at a medical meeting in
the second half of this year. In addition, we look forward to initiating our CD38-SADA Phase 1 trial this year. While we continue to advance
our SADA PRIT platform and programs through clinical development, we are supported by the solid commercial performance of DANYELZA®
(naxitamab-gqgk). We achieved record quarterly and annual net product revenues, and sales continue trending upward as more high-volume
centers deploy DANYELZA for their patients. Our strong financial foundation and operational performance continue to fuel our mission of
providing better and safe therapies for a variety of cancers and improve the lives of patients and their families.”
Fourth Quarter 2023 and Recent
Corporate Developments
| · | In December 2023, Y-mAbs announced that it was added to the NASDAQ Biotechnology
Index (NASDAQ: NBI), effective December 18, 2023. |
| · | On October 18, 2023, Y-mAbs announced that its Board of Directors appointed
radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023. Thomas
Gad, who founded Y-mAbs in 2015 and has served as Interim Chief Executive Officer since 2022, transitioned to the role of Vice Chairman
of the Board of Directors and Chief Business Officer. |
| · | On October 17, 2023, the U.S. FDA cleared Y-mAbs’ IND for CD38-SADA,
marking the second clinical development program utilizing the Company’s novel SADA PRIT technology platform. |
| · | On October 16, 2023, Y-mAbs announced the publication of a study of
naxitamab-based chemoimmunotherapy (“HITS”) study in patients with refractory high-risk neuroblastoma (“HR-NB”)
in the journal Cancers. The study investigated the HITS combination in patients with HR-NB who did not respond well to induction
or refractory therapy. Patients who received HITS immediately after induction had higher response rates (47% vs. 18%) and superior estimated
three-year overall survival (85% vs. 29%), compared with those who received the same combination regimen later in the course of treatment.
The publication is entitled, “Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for
Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.” |
| · | On October 11, 2023, Y-mAbs showcased three poster presentations, in
addition to an online publication, of DANYELZA at the 55th Congress of the International Society of Pediatric Oncology in Ottawa,
Canada. |
Financial Results
Revenues
DANYELZA net product revenues were $23.4 million and $84.3 million
for the quarter and year ended December 31, 2023, which represented increases of 42% and 71%, respectively, over $16.4 million and
$49.3 million in the comparable periods of 2022. The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented
a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
As of December 31, 2023, Y-mAbs
has delivered DANYELZA to 58 centers across the U.S. since initial launch, with ten new accounts added in 2023.
The Company did not have license revenues in the quarter ended December 31,
2023 and had license revenues of $0.5 million for the year ended December 31, 2023. The Company reported license revenues of $15.0
million and $16.0 million for the quarter and year ended December 31, 2022. License revenues for the year ended December 31,
2023 arose from the September 2023 achievement of marketing authorization for DANYELZA in Mexico under the Company’s sublicense
agreement with Adium. During the quarter and year ended December 31, 2022, the Company recognized a regulatory-based milestone of
$15.0 million from SciClone Pharmaceuticals International Ltd. for the conditional approval of DANYELZA in China.
Operating Costs and Expenses
Cost of Goods Sold
Cost of goods sold was $2.0 million for the quarters ended December 31,
2023 and 2022, respectively. The cost of goods sold was $11.4 million and $7.5 million for the years ended December 31, 2023, and
2022, respectively. The increase in cost of goods sold in both periods was primarily driven by increased product revenues. The Company
experienced inventory write-downs of $0.8 million and $1.2 million in the years ended December 31, 2023, and December 31, 2022,
respectively.
The Company’s gross margin, excluding the 2023 and 2022 inventory
write-downs, increased in the fourth quarter of 2023 to 91% due to the gross margin increase from higher U.S. revenues. The Company’s
gross margin, excluding the 2023 and 2022 inventory write-downs, remained constant at 87% for the year ended December 31, 2023, compared
to the year ended December 31, 2022, which was the net impact of the gross margin increase from higher U.S. revenues, offset by increased
revenues from geographic areas outside the U.S., which were at a lower gross margin. The Company defines gross margin as net product revenues
less cost of goods sold divided by net product revenues.
Research and Development
Research and development expenses were $13.4 million for the quarter
ended December 31, 2023, a reduction of 32% compared to $19.8 million for the quarter ended December 31, 2022. The $6.4 million
decrease was primarily due to decreased spending on deprioritized programs, which resulted in a $3.1 million decrease in outsourced manufacturing,
a $2.0 million decrease in personnel-related costs, inclusive of stock-based compensation, and a $2.2 million decrease in outsourced research
and supplies, partially offset by a $1.2 million increase in clinical trials expenses.
For the year ended December 31, 2023, research and development
expenses were $54.2 million, a reduction of 41% compared to $91.6 million for the year ended December 31, 2022. The $37.4 million
decrease was primarily due to decreased spending on deprioritized programs, resulting in a $21.0 million decrease in outsourced manufacturing,
a $9.0 million decrease in outsourced research and supplies, a $6.1 million decrease in personnel-related costs, inclusive of stock-based
compensation, and a $2.0 million decrease in clinical trials, partially offset by a $3.8 million increase in milestones and license acquisition
costs primarily related to a $4.1 million increase in milestones accrued under the Company’s SADA License Agreement, as the Company
determined that achievement of certain time-based clinical milestones within the agreement are probable based on the availability of data
and the assessment of clinical progress in the year of 2023.
The $2.0 million and $6.1 million decreases in personnel-related costs
during the quarter and year ended December 31, 2023, respectively, were driven by the headcount reduction as part of the Company’s
restructuring plan announced in January 2023. The expense reduction in the year ended December 31, 2023 was partially offset
by severance charges recognized in conjunction with the restructuring plan.
Selling, General, and Administration
Selling, general, and administrative expenses were $11.1 million for
the quarter ended December 31, 2023, which was a slight increase compared to $10.8 million for the quarter ended December 31,
2022.
For the year ended December 31, 2023, selling, general, and administrative
expenses were $44.9 million, a reduction of 26% compared to $60.9 million for the year ended December 31, 2022. The $16.0 million
decrease in selling, general and administrative expenses was primarily attributable to a $10.9 million charge in the year ended December 31,
2022 related to contractual severance-related benefits for the Company’s former Chief Executive Officer, and, to a lesser extent,
a $3.4 million decrease in commercialization expenses, inclusive of costs of incurred in 2022 in anticipation of a potential omburtamab
launch.
Interest and Other Income/(Loss)
Interest and other income/(loss) was relatively unchanged at $2.4 million
as compared to $2.3 million during the quarters ended December 31, 2023 and 2022, respectively. Interest and other income/(loss)
was $4.8 million of income as compared to $0.8 million of loss for the years ended December 31, 2023 and 2022, respectively. The
$5.6 million favorable change in interest and other income/(loss), reflects increased interest income for the year ended December 31,
2023, and was driven by increased money market fund investment income. The Company recorded impairment charges totaling $1.4 million related
to the write down of two Secured Promissory Notes during the year ended December 31, 2022.
Net Loss
Y-mAbs reported a net loss for the quarter ended December 31,
2023, of $1.0 million, or ($0.02) per basic and diluted share, compared to net income of $1.2 million, or $0.03 per basic and diluted
share, for the quarter ended December 31, 2022. The net income for the quarter ended December 31, 2022, was after $15.0 million
of license revenue recognized in the fourth quarter of 2022. For the year ended December 31, 2023, the Company reported a net loss
of $21.4 million, or ($0.49) per basic and diluted share, compared to a net loss of $95.6 million, or ($2.19) per basic and diluted share,
for the year ended December 31, 2022. The favorable decrease in net loss for the year ended December 31, 2023, was primarily
driven by an increase in U.S. and international DANYELZA product revenues for the year ended December 31, 2023, as well as decreased
research and development cost, and decreased selling, general and administration cost.
Cash and Cash Equivalents
As of December 31, 2023, Y-mAbs
had approximately $78.6 million in cash and cash equivalents which, together with anticipated DANYELZA product revenues, is expected
to support operations as currently planned into 2027. This estimate reflects the Company’s current business plan that is supported
by assumptions that may prove to be inaccurate, such that Y-mAbs could use its available capital resources sooner than it currently expects.
2024 Financial Guidance
| · | Anticipated
DANYELZA® net product revenues of between $95 million and $100 million; |
| · | Anticipated
operating expenses of between $115 million and $120 million; |
| · | Anticipated
total annual cash burn of between $15 million and $20 million; and |
| · | Cash
and cash equivalents anticipated to continue to support operations as currently planned into
2027. |
Webcast and Conference Call
Y-mAbs will host a conference call on Friday, March 1, 2024, at
8:00 a.m. ET. To participate in the call, please use the following dial-in information.
| Investors (domestic): |
(877) 407-0792 |
| Investors (international): |
(201) 689-8263 |
| Conference ID: |
13744085 |
To
access a live webcast of the update, please use this link.
Prior to the call and webcast, a slide presentation pertaining to our quarterly earnings will be made available in the investor relations
section of our website, www.ymabs.com, shortly before the call begins.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the
development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies
include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy
Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s
broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for
patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable
disease to prior therapy.
Forward-Looking
Statements
Statements in this press release about
future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial
outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources
and related assumptions; implied and express statements regarding the future of the Company’s business, including with respect to
expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans, including
potential partnerships; expectations with respect to the Company’s products and product candidates, including otential territory
and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential
of the SADA Technology and potential benefits and applications thereof; statements with respect to DANYELZA as a growing commercial product
and SADA as a differentiated radioimmunotherapy platform positioning the Company on a path to potentially transform the treatment paradigm
for a variety of cancers and improve patients’ lives; expectations relating to key anticipated development milestones, including
potential expansion of international commercialization efforts with respect to DANYELZA development efforts and the SADA Technology, including
potential indications and applications, and the timing thereof; expectations with respect to current and future clinical and pre-clinical
studies and the Company’s research and development programs, including with respect to timing and results; expectations related
to the timing of the initiation and completion of regulatory submissions; additional product candidates and technologies; expectations
regarding collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of cash and cash
equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s
future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’
‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’
‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’
‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’,
“guidance,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that
present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result
of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional
capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks
associated with the Company’s development work; cost and success of the Company’s product development activities and clinical
trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates;
the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product
candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products;
the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture;
the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval,
risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth;
risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia
and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict,
inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and
uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q
for the quarter ended September 30, 2023 and future filings and reports by the Company. Any forward-looking statements contained
in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
DANYELZA®,
OMBLASTYS® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
Y-MABS THERAPEUTICS, INC.
Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share data)
| | |
As of | |
| | |
December 31, | | |
December 31, | |
| | |
2023 | | |
2022 | |
| ASSETS | |
| | | |
| | |
| CURRENT ASSETS | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 78,637 | | |
$ | 105,762 | |
| Accounts receivable, net | |
| 22,454 | | |
| 12,531 | |
| Inventories | |
| 5,065 | | |
| 6,702 | |
| Other current assets | |
| 4,955 | | |
| 5,452 | |
| Total current assets | |
| 111,111 | | |
| 130,447 | |
| Property and equipment, net | |
| 224 | | |
| 604 | |
| Operating lease right-of-use assets | |
| 1,412 | | |
| 1,739 | |
| Intangible assets, net | |
| 2,631 | | |
| 2,986 | |
| Other assets | |
| 12,491 | | |
| 5,680 | |
| TOTAL ASSETS | |
$ | 127,869 | | |
$ | 141,456 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| LIABILITIES | |
| | | |
| | |
| Accounts payable | |
$ | 6,060 | | |
$ | 14,175 | |
| Accrued liabilities | |
| 13,166 | | |
| 13,241 | |
| Operating lease liabilities, current portion | |
| 902 | | |
| 868 | |
| Total current liabilities | |
| 20,128 | | |
| 28,284 | |
| Accrued milestone payments | |
| 5,375 | | |
| 2,250 | |
| Operating lease liabilities, long-term portion | |
| 517 | | |
| 899 | |
| Other liabilities | |
| 864 | | |
| 802 | |
| TOTAL LIABILITIES | |
| 26,884 | | |
| 32,235 | |
| | |
| | | |
| | |
| STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Preferred stock, $0.0001 par value, 5,500,000 shares authorized and none issued at December 31, 2023 and December 31, 2022 | |
| - | | |
| - | |
| Common stock, $0.0001 par value, 100,000,000 shares authorized at December 31, 2023 and December 31, 2022; 43,672,112 and 43,670,109 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | |
| 4 | | |
| 4 | |
| Additional paid-in capital | |
| 558,002 | | |
| 543,929 | |
| Accumulated other comprehensive income | |
| 449 | | |
| 1,331 | |
| Accumulated deficit | |
| (457,470 | ) | |
| (436,043 | ) |
| TOTAL STOCKHOLDERS’ EQUITY | |
| 100,985 | | |
| 109,221 | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 127,869 | | |
$ | 141,456 | |
Y-MABS THERAPEUTICS, INC.
Consolidated Statements of Net Loss and Comprehensive Loss
(unaudited)
(In thousands, except share and per share data)
| | |
Three months ended December 31, | | |
Years ended December 31, | |
| | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| REVENUES | |
| | | |
| | | |
| | | |
| | |
| Product revenue, net | |
$ | 23,363 | | |
$ | 16,447 | | |
$ | 84,319 | | |
$ | 49,267 | |
| License revenue | |
| — | | |
| 15,000 | | |
| 500 | | |
| 16,000 | |
| Total revenues | |
| 23,363 | | |
| 31,447 | | |
| 84,819 | | |
| 65,267 | |
| OPERATING COSTS AND EXPENSES | |
| | | |
| | | |
| | | |
| | |
| Cost of goods sold | |
| 2,039 | | |
| 2,020 | | |
| 11,366 | | |
| 7,467 | |
| License royalties | |
| — | | |
| — | | |
| 50 | | |
| 100 | |
| Research and development | |
| 13,388 | | |
| 19,787 | | |
| 54,219 | | |
| 91,572 | |
| Selling, general, and administrative | |
| 11,135 | | |
| 10,793 | | |
| 44,856 | | |
| 60,939 | |
| Total operating costs and expenses | |
| 26,562 | | |
| 32,600 | | |
| 110,491 | | |
| 160,078 | |
| Loss from operations | |
| (3,199 | ) | |
| (1,153 | ) | |
| (25,672 | ) | |
| (94,811 | ) |
| OTHER INCOME/(LOSS), NET | |
| | | |
| | | |
| | | |
| | |
| Interest and other income/(loss) | |
| 2,406 | | |
| 2,310 | | |
| 4,806 | | |
| (757 | ) |
| LOSS BEFORE INCOME TAXES | |
| (793 | ) | |
| 1,157 | | |
| (20,866 | ) | |
| (95,568 | ) |
| Provision for income taxes | |
| 195 | | |
| — | | |
| 561 | | |
| — | |
| NET INCOME/(LOSS) | |
$ | (988 | ) | |
$ | 1,157 | | |
$ | (21,427 | ) | |
$ | (95,568 | ) |
| Other comprehensive loss | |
| | | |
| | | |
| | | |
| | |
| Foreign currency translation | |
| (1,400 | ) | |
| (3,371 | ) | |
| (882 | ) | |
| (40 | ) |
| COMPREHENSIVE LOSS | |
$ | (2,388 | ) | |
$ | (2,214 | ) | |
$ | (22,309 | ) | |
$ | (95,608 | ) |
| Net income/(loss) per share attributable to common stockholders, basic | |
$ | (0.02 | ) | |
$ | 0.03 | | |
$ | (0.49 | ) | |
$ | (2.19 | ) |
| Weighted average common shares outstanding, basic | |
| 43,627,270 | | |
| 43,668,690 | | |
| 43,645,388 | | |
| 43,703,663 | |
| Net income/(loss) per share attributable to common stockholders, diluted | |
$ | (0.02 | ) | |
$ | 0.03 | | |
$ | (0.49 | ) | |
$ | (2.19 | ) |
| Weighted average common shares outstanding, diluted | |
| 43,627,270 | | |
| 44,692,485 | | |
| 43,645,388 | | |
| 43,703,663 | |
v3.24.0.1
Cover
|
Feb. 29, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Feb. 29, 2024
|
| Entity File Number |
001-38650
|
| Entity Registrant Name |
Y-MABS THERAPEUTICS, INC.
|
| Entity Central Index Key |
0001722964
|
| Entity Tax Identification Number |
47-4619612
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
230 Park Avenue
|
| Entity Address, Address Line Two |
Suite 3350
|
| Entity Address, City or Town |
New York
|
| Entity Address, State or Province |
NY
|
| Entity Address, Postal Zip Code |
10169
|
| City Area Code |
646
|
| Local Phone Number |
885-8505
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, $0.0001 par value
|
| Trading Symbol |
YMAB
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Apr 2023 to Apr 2024
